HKEX: 1541
Next Day Disclosure Return
Earlier from Immuneonco Biopharmaceuticals (shanghai) Inc Class H
- Voluntary announcement - completion of capital increase of a subsidiary
- 2026 Interim Report
- Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)